- Home
- DXR vs VERU Comparison
DXR vs VERU Comparison
Compare DXR & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- VERU
- Stock Information
- Founded
- DXR 1970
- VERU 1971
- Country
- DXR United States
- VERU United States
- Employees
- DXR N/A
- VERU N/A
- Industry
- DXR Medical/Dental Instruments
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- VERU Health Care
- Exchange
- DXR Nasdaq
- VERU Nasdaq
- Market Cap
- DXR 46.9M
- VERU 54.6M
- IPO Year
- DXR N/A
- VERU 1990
- Fundamental
- Price
- DXR $13.50
- VERU $4.29
- Analyst Decision
- DXR Strong Buy
- VERU Strong Buy
- Analyst Count
- DXR 1
- VERU 3
- Target Price
- DXR $25.00
- VERU $33.33
- AVG Volume (30 Days)
- DXR 5.1K
- VERU 158.4K
- Earning Date
- DXR 01-01-0001
- VERU 08-12-2025
- Dividend Yield
- DXR N/A
- VERU N/A
- EPS Growth
- DXR 3.46
- VERU N/A
- EPS
- DXR 0.36
- VERU N/A
- Revenue
- DXR $66,306.00
- VERU $16,886,419.00
- Revenue This Year
- DXR N/A
- VERU N/A
- Revenue Next Year
- DXR N/A
- VERU N/A
- P/E Ratio
- DXR $38.30
- VERU N/A
- Revenue Growth
- DXR N/A
- VERU 337.24
- 52 Week Low
- DXR $6.55
- VERU $2.64
- 52 Week High
- DXR $14.00
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- DXR 66.65
- VERU 74.55
- Support Level
- DXR $13.39
- VERU $3.75
- Resistance Level
- DXR $14.00
- VERU $3.99
- Average True Range (ATR)
- DXR 0.50
- VERU 0.24
- MACD
- DXR 0.13
- VERU -0.01
- Stochastic Oscillator
- DXR 80.93
- VERU 94.34
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.